NCT04328506View on ClinicalTrials.gov

Bioequivalency Study of CM082 Tablet in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

July 27, 2020

Study Completion Date

July 27, 2020

Conditions
Advanced Malignant Solid Tumors
Interventions
DRUG

CM082 tablet (test product)

Test product(T)：100mg CM082 tablet manufactured by Betta Pharmaceuticals

DRUG

CM082 tablet (reference product)

Reference product(R)：100mg CM082 tablet manufactured by Catalent Pharma Solutions

Trial Locations (1)

311009

The 1st Phase Clinical Research Center of the Second Affiliated Hospital of Zhejiang University Medical College, Hangzhou

Sponsors

Lead Sponsor

AnewPharma
All Listed Sponsors
lead

AnewPharma

INDUSTRY

NCT04328506 - Bioequivalency Study of CM082 Tablet in Healthy Volunteers | Biotech Hunter | Biotech Hunter